Reauthorization of FDA user fee agreements will strengthen dialogue and advance innovation, BIO’s Chief Scientific Officer Dr. Cartier Esham told the Senate Health, Education, Labor …
BIO’s CSO tells Senate PDUFA is ‘critical to advancing innovation’ Read More »
Legislation to modernize the clinical drug development paradigm should be patient-centric, effective and inclusive, BIO’s Chief Scientific Officer Dr. Cartier Esham told a House panel …
BIO’s CSO testifies at congressional hearing on PDUFA riders Read More »
The United States, European Union, India, and South Africa “reached a consensus on key elements of a long-sought intellectual property waiver for COVID-19 vaccines” Reuters …
Agreement reported on waiver of COVID vaccine IP protections; details forthcoming Read More »
Phyllis Arthur, Vice President of Infectious Diseases & Emerging Science at the Biotechnology Innovation Organization (BIO), published an op-ed about pandemic preparedness in INSIDESOURCES. The …
BIO VP: The PREVENT Pandemics Act Is a Great Step Forward – But Not the Finish Line Read More »
An opinion piece in the San-Jose Mercury News argues against forcing drug makers to allow for generic versions of their products simply because their research …
Other Voices: ‘Don’t sacrifice the miracle of American innovation’ Read More »
Russia’s decision to wage war on Ukraine brought home in very dramatic terms the urgency of weaning ourselves from fossil fuels, and creating more stable …
War brings home urgency of alternative fuels, food stability Read More »
The Food and Drug Administration (FDA) on Friday announced approval of using nivolumab in certain procedures for treating non-small cell lung cancer (NSCLC), the most …
FDA approves new drug for most-common lung cancer Read More »
Gene editing can improve the health and welfare of animals, and the sustainability of our food supply, Elena Rice, CSO of Genus PLC told the …
USDA Forum told of gene editing benefits for animals and people Read More »
The FDA on Thursday announced approval of Jardiance to reduce the risk of death and hospitalization in adult patients with heart failure. Originally approved in …
FDA approves Jardiance for wider range of heart failure patients Read More »
The CEO of a biopharma firm working on a treatment for a rare, fatal pediatric syndrome says the CMS decision to restrict coverage for an …
Other Voices: ‘CMS decision puts future disease cures in crosshairs’ Read More »
